Rallybio Phase 2 trial of RLYB212 begins to tackle FNAIT in high-risk pregnancies

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company known for advancing innovative therapies for rare diseases, has commenced its Phase 2 clinical trial for RLYB212. ... Read More